TITLE

Denosumab for treatment of postmenopausal osteoporosis

AUTHOR(S)
Chitre, Mona; Shechter, David; Grauer, Andreas
PUB. DATE
August 2011
SOURCE
American Journal of Health-System Pharmacy;8/1/2011, Vol. 68 Issue 15, p1409
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The pharmacologic properties, clinical efficacy, and safety profile of the injectable agent denosumab for the treatment of postmenopausal women with osteoporosis are reviewed. Summary. Denosumab, a human monoclonal antibody that targets a key protein mediator of bone resorption, was approved by the Food and Drug Administration in June 2010 for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture, including "patients who have failed or are intolerant to other available osteoporosis therapy." Available in a 60-mg prefilled syringe, denosumab should be administered subcutaneously by a health care professional at six-month intervals. In Phase III clinical efficacy trials involving nearly 10,000 postmenopausal women, the use of denosumab was associated with a number of significant benefits: reduced bone resorption, increased bone mass, and reduced rates of vertebral, nonvertebral, and hip fractures. Results of two comparison studies indicated that denosumab therapy increased bone mineral density (BMD) at various skeletal sites to a significantly greater extent than alendronate therapy. In the largest clinical trial of the drug to date, adverse effects occurring significantly more often with denosumab versus placebo included eczema-related effects and cellulitis; long-term safety evaluations are ongoing. Conclusion. Denosumab has been shown to decrease bone resorption; increase BMD at all skeletal sites measured; and significantly reduce rates of vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis. Denosumab appears to have a favorable risk:benefit profile and provides a new treatment option for many patients in this population.
ACCESSION #
63627099

 

Related Articles

  • MAGIC BULLETS WITH A HEFTY PRICE TAG. Shaughnessy, Allen // BMJ: British Medical Journal;12/15/2012, Vol. 345 Issue 7887, p18 

    The article discusses the sale and use of monoclonal antibodies such as Alemtuzumab and Natalizumab and their marketing by drug manufacturing companies. It explains the use of monoclonal antibodies for treatment and the evidence supporting it. It states the reason for expensiveness of monoclonal...

  • Osteoporosis Injection Shows Long-Term Efficacy in Increasing Bone Mineral Density.  // Journal of Gerontological Nursing;Jul2011, Vol. 37 Issue 7, p16 

    The article focuses on long-term data concerning treatment with denosumab into the fourth and fifth year by postmenopausal women with osteoporosis. It states that there were statistically significant, year-over-year increases in total hip and lumbar spine bone mineral density. It mentions that...

  • Denosumab: A Review of its Use in Postmenopausal Women with Osteoporosis. Scott, Lesley // Drugs & Aging;Jul2014, Vol. 31 Issue 7, p555 

    Subcutaneous denosumab (Prolia [USA, Europe]; Pralia [Japan]) once every 6 months is indicated in several countries for the treatment of postmenopausal women with osteoporosis at increased or high risk for fractures (featured indication). In some countries, it is also indicated for use in...

  • Novel treatment for UC at a discount.  // Gastrointestinal Nursing;Apr2015, Vol. 13 Issue 3, p12 

    The article reports that the National Institute for Health and Care Excellence has placed a condition on the use of Entyvio for the treatment of ulcerative colitis for manufacturers to offer a discount.

  • Osteoporosis treatment options expand.  // Mayo Clinic Health Letter;Nov2010, Vol. 28 Issue 11, p4 

    The article offers information on Denosumab (Prolia), a twice-yearly injectable drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of osteoporosis.

  • Breast Cancer Drug Appears to Extend Patients' Lives by 15 Months. MCBRIDE, DEBORAH // ONS Connect;Dec2014, Vol. 29 Issue 4, p35 

    The article discusses research which investigated the effectiveness of monoclonal antibody pertuzumab in improving survival of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Topics explored include the combination of pertuzumab and trastuzumab in blocking...

  • Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Hadji, P.; Papaioannou, N.; Gielen, E.; Feudjo Tepie, M.; Zhang, E.; Frieling, I.; Geusens, P.; Makras, P.; Resch, H.; Möller, G.; Kalouche-Khalil, L.; Fahrleitner-Pammer, A. // Osteoporosis International;Oct2015, Vol. 26 Issue 10, p2479 

    Summary: Persistence with and adherence to osteoporosis therapy are critical for fracture reduction. This non-interventional study is evaluating medication-taking behavior of women with postmenopausal osteoporosis (PMO) receiving denosumab in Germany, Austria, Greece, and Belgium. Patients were...

  • Implications and benefits of the NICE appraisal of pembrolizumab. Danson, Sarah // British Journal of Healthcare Management;Nov2015, Vol. 21 Issue 11, p506 

    No abstract available.

  • Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study. Silverman, S.; Siris, E.; Kendler, D.; Belazi, D.; Brown, J.; Gold, D.; Lewiecki, E.; Papaioannou, A.; Simonelli, C.; Ferreira, I.; Balasubramanian, A.; Dakin, P.; Ho, P.; Siddhanti, S.; Stolshek, B.; Recknor, C. // Osteoporosis International;Jan2015, Vol. 26 Issue 1, p361 

    Summary: To determine persistence with subcutaneous denosumab every 6 months in women being treated for osteoporosis, we conducted a single-arm prospective, observational study in the United States and Canada. Among 935 patients enrolled, 12-month persistence was 82 %, with 66 patients (7 %)...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics